Palisade Bio Inc Cash Flow Conversion Efficiency
Palisade Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Palisade Bio Inc (PALI) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($121.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Palisade Bio Inc (2005–2025)
Cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2025. This chart illustrates how Palisade Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Palisade Bio Inc stock quote for real-time trading data and today's change.
Palisade Bio Inc Cash Flow Conversion Ratio Explained
Palisade Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Palisade Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palisade Bio Inc ranked by their cash flow conversion efficiency. Also see PALI market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
0.049x |
|
TuanChe ADR
NASDAQ:TC
|
-0.641x |
|
Ginwa Enterprise Group Inc
SHG:600080
|
0.019x |
|
Darwin Precisions Corp
TW:6120
|
-0.077x |
|
The Orissa Minerals Development Company Limited
NSE:ORISSAMINE
|
0.738x |
|
Prodware
PA:ALPRO
|
0.142x |
|
JS Corp
KO:194370
|
0.099x |
|
Kumho Ind
KO:002990
|
0.071x |
Annual Cash Flow Conversion Efficiency for Palisade Bio Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2025. Review Palisade Bio Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $129.38 Million | $-10.85 Million | -0.084x | +94.85% |
| 2024-12-31 | $7.49 Million | $-12.19 Million | -1.627x | -65.38% |
| 2023-12-31 | $11.31 Million | $-11.13 Million | -0.984x | +8.08% |
| 2022-12-31 | $12.48 Million | $-13.36 Million | -1.071x | +46.63% |
| 2021-12-31 | $7.37 Million | $-14.77 Million | -2.006x | -398.65% |
| 2020-12-31 | $-7.10 Million | $-4.77 Million | 0.672x | +147.45% |
| 2019-12-31 | $5.13 Million | $-7.26 Million | -1.415x | -11.32% |
| 2018-12-31 | $6.05 Million | $-7.69 Million | -1.272x | +19.29% |
| 2017-12-31 | $8.52 Million | $-13.42 Million | -1.576x | -14.32% |
| 2016-12-31 | $11.33 Million | $-15.62 Million | -1.378x | +63.84% |
| 2015-12-31 | $4.97 Million | $-18.93 Million | -3.811x | -476.88% |
| 2014-12-31 | $17.72 Million | $-11.71 Million | -0.661x | +47.49% |
| 2013-12-31 | $8.42 Million | $-10.59 Million | -1.258x | -3.48% |
| 2012-12-31 | $6.97 Million | $-8.48 Million | -1.216x | +75.08% |
| 2011-12-31 | $1.66 Million | $-8.10 Million | -4.878x | -283.86% |
| 2010-12-31 | $7.85 Million | $-9.98 Million | -1.271x | -223.88% |
| 2009-12-31 | $-5.02 Million | $-5.14 Million | 1.026x | +162.85% |
| 2008-12-31 | $4.20 Million | $-6.86 Million | -1.632x | -177.74% |
| 2007-12-31 | $6.81 Million | $-4.00 Million | -0.588x | +72.65% |
| 2006-12-31 | $1.55 Million | $-3.33 Million | -2.148x | -235.69% |
| 2005-12-31 | $-460.17K | $-728.59K | 1.583x | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more